移植相关性血栓性微血管病临床研究
Clinical Study of Transplant-Associated Thrombotic Microangiopathy
DOI: 10.12677/ACM.2022.12111564, PDF,   
作者: 张赵光：山东第一医科大学，山东 济南；董 琳*：山东第一医科大学第一附属医院(山东省千佛山医院)血液病学，山东 济南
关键词: 造血干细胞移植；造血干细胞移植相关性血栓微血管病；补体激活；Hematopoietic Stem Cell Transplantation； Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy； Complement Activation
摘要: 造血干细胞移植(Hematopoietic stem cell transplant HSCT)相关血栓性微血管病(Hematopoietic stem cell transplant-associated thrombotic microangiopathy TA-TMA)是公认的移植后出现的严重并发症。其特征是微血管病性溶血性贫血、原因不明的血小板减少症、乳酸脱氢酶(Lactate dehydrogenase, LDH)升高和内皮损伤所致相关器官衰竭为特征，如高血压、慢性肾病、肺动脉高压、胃肠道或中枢神经系统疾病。TA-TMA的临床表现与血栓性血小板减少性紫癜(thrombotic thrombocytopenic purpura, TTP)和非典型溶血性尿毒症综合征(atypical haemolytic uraemic syndrome, aHUS)相似，后两者以微血管病性溶血性贫血、血小板消耗、微循环纤维蛋白沉积以及最终的终末器官损伤为特征。由于该病起病隐匿，进展迅速，对其认识不足，经常造成漏诊和误诊。我们应该及早发现，及早干预，降低患者死亡风险。
Abstract: Hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy TA-TMA is rec-ognized as a serious complication after transplantation. It is characterized by microangiopathic he-molytic anemia, unexplained thrombocytopenia, elevated lactate dehydrogenase (LDH), and related organ failure due to endothelial damage, such as hypertension, chronic kidney disease, pulmonary hypertension, gastrointestinal or central nervous system diseases. The clinical manifestations of TA-TMA were correlated with thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic uraemic syndrome (aHUS), characterized by microangiopathic hemolytic anemia, platelet depletion, microcirculating fibrin deposition, and eventual end-organ damage. Due to the hidden onset, rapid progress and insufficient understanding of the disease, it often leads to missed diagnosis and misdiagnosis. We should make early detection and intervention to reduce the risk of death.
文章引用：张赵光, 董琳. 移植相关性血栓性微血管病临床研究[J]. 临床医学进展, 2022, 12(11): 10863-10869. https://doi.org/10.12677/ACM.2022.12111564

参考文献

[1] Van Benschoten, V., Roy, C., et al. (2022) Incidence and Risk Factors of Transplantation-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 28, 266.e1-266.e8. [Google Scholar] [CrossRef] [PubMed]
[2] Li, A., Bhatraju, P.K., Chen, J., et al. (2021) Prognostic Biomarkers for Thrombotic Microangiopathy after Acute Graft-versus-Host Disease: A Nested Case-Control Study. Transplantation and Cellular Therapy, 27, 308.e1-308.e8. [Google Scholar] [CrossRef] [PubMed]
[3] Punatar, S., Kalantri, S.A., Chichra, A., et al. (2021) Pre-Transplant Use of Tyrosine Kinase Inhibitors and Transplant Associated Thrombotic Microangiopathy—A Single Centre Analysis of Incidence, Risk Factors and Outcomes. Bone Marrow Transplantation, 56, 1558-1562. [Google Scholar] [CrossRef] [PubMed]
[4] Khosla, J., Yeh, A.C., Spitzer, T.R. and Dey, B.R. (2018) Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy: Current Paradigm and Novel Therapies. Bone Marrow Transplantation, 53, 129-137. [Google Scholar] [CrossRef] [PubMed]
[5] Goldberg, R.J., Nakagawa, T., Johnson, R.J. and Thurman, J.M. (2010) The Role of Endothelial Cell Injury in Thrombotic Microangiopathy. American Journal of Kidney Diseases, 56, 1168-1174. [Google Scholar] [CrossRef] [PubMed]
[6] Willems, E., Baron, F., Seidel, L., et al. (2010) Comparison of Thrombotic Microangiopathy after Allogeneic Hematopoietic Cell Transplantation with High-Dose or Nonmyeloablative Conditioning. Bone Marrow Transplantation, 45, 689-693. [Google Scholar] [CrossRef] [PubMed]
[7] Jodele, S., Licht, C., Goebel, J., Dixon, B.P., Zhang, K., Sivakumaran, T.A., et al. (2013) Abnormalities in the Alternative Pathway of Complement in Children with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy. Blood, 122, 2003-2007. [Google Scholar] [CrossRef] [PubMed]
[8] Qi, J., Pan, T., You, T., et al. (2022) Upregulation of HIF-1α Contributes to Complement Activation in Transplantation-Associated Thrombotic Microangiopathy. British Journal of Haematology, 199, 603-615. [Google Scholar] [CrossRef] [PubMed]
[9] Ricklin, D. and Cines, D.B. (2013) TMA: Beware of Complements. Blood, 122, 1997-1999. [Google Scholar] [CrossRef] [PubMed]
[10] Jan, A.S., Hosing, C., Aung, F. and Yeh, J. (2019) Ap-proaching Treatment of Transplant-Associated Thrombotic Microangiopathy from Two Directions with Eculizumab and Transitioning from Tacrolimus to Sirolimus. Transfusion, 59, 3519-3524. [Google Scholar] [CrossRef] [PubMed]
[11] Zhao, Y., Zhang, L., Qiao, Y., et al. (2013) Heme Oxygenase-1 Prevents Cardiac Dysfunction in Streptozotocin-Diabetic Mice by Reducing Inflammation, Oxidative Stress, Apoptosis and En-hancing Autophagy. PLOS ONE, 8, e75927. [Google Scholar] [CrossRef] [PubMed]
[12] Tu, C.F., Tai, H.C., et al. (2010) The in Vitro Protection of Human Decay Accelerating Factor and hDAF/Heme Oxygenase-1 Transgenes in Porcine Aortic Endothelial Cells against Sera of Formosan Macaques. Transplantation Proceedings, 42, 2138-2141. [Google Scholar] [CrossRef] [PubMed]
[13] Elemary, M., Sabry, W., Seghatchian, J. and Goubran, H. (2019) Transplant-Associated Thrombotic Microangiopathy: Diagnostic Challenges and Management Strategies. Transfusion and Apheresis Science, 58, 347-350. [Google Scholar] [CrossRef] [PubMed]
[14] Mezö, B., Horváth, O., Sinkovits, G., et al. (2020) Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation. Frontiers in Medicine (Lausanne), 7, Article ID: 569291. [Google Scholar] [CrossRef] [PubMed]
[15] Jodele, S., Laskin, B.L., Dandoy, C.E., et al. (2015) A New Para-digm: Diagnosis and Management of HSCT-Associated Thrombotic Microangiopathy as Multi-System Endothelial In-jury. Blood Reviews, 29, 191-204. [Google Scholar] [CrossRef] [PubMed]
[16] Dandoy, C., Davies, S.M., Hirsch, R., Chima, R.S., Paff, Z., Cash, M., et al. (2014) Abnormal Echocardiography Seven Days after Stem Cell Transplant May Be an Early Indicator of Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 21, 113-118. [Google Scholar] [CrossRef] [PubMed]
[17] El-Bietar, J., Warren, M., Dandoy, C., et al. (2015) Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 21, 1994-2001. [Google Scholar] [CrossRef] [PubMed]
[18] Dhakal, P. and Bhatt, V.R. (2017) Is Complement Blockade an Acceptable Therapeutic Strategy for Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy? Bone Marrow Transplantation, 52, 352-356. [Google Scholar] [CrossRef] [PubMed]
[19] Cho, B.S., Yahng, S.A., Lee, S.E., et al. (2010) Validation of Recently Proposed Consensus Criteria for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem-Cell Transplantation. Transplantation, 90, 918-926. [Google Scholar] [CrossRef] 
[20] Laskin, B.L., Goebel, J., Davies, S.M., et al. (2011) Early Clinical Indicators of Transplant-Associated Thrombotic Microangiopathy in Pediatric Neuroblastoma Patients Undergo-ing Auto-SCT. Bone Marrow Transplantation, 46, 682-689. [Google Scholar] [CrossRef] [PubMed]
[21] Ishikawa, Y., Nishio, S., Sasaki, H., et al. (2011) Transplanta-tion-Associated Thrombotic Microangiopathy after Steroid Pulse Therapy for Polyserositis Related to Graft-versus-Host Disease. Clinical and Experimental Nephrology, 15, 179-183. [Google Scholar] [CrossRef] [PubMed]
[22] Ruutu, T., Barosi, G., Benjamin, R.J., et al. (2007) Diagnostic Criteria for Hematopoietic Stem Cell Transplant-Associated Microangiopathy: Results of a Consensus Process by an International Working Group. Haematologica, 92, 95-100. [Google Scholar] [CrossRef] [PubMed]
[23] Rudoni, J., Jan, A., Hosing, C., Aung, F. and Yeh, J. (2018) Eculizumab for Transplant-Associated Thrombotic Microangiopathy in Adult Allogeneic Stem Cell Transplant Recipients. European Journal of Haematology, 101, 389-398. [Google Scholar] [CrossRef] [PubMed]
[24] 中华医学会血液学分会造血干细胞应用学组. 造血干细胞移植相关血栓性微血管病诊断和治疗中国专家共识(2021年版) [J]. 中华血液学杂志, 2021, 42(3): 177-184.
[25] Jodele, S., Davies, S.M., Lane, A., et al. (2014) Diagnostic and Risk Criteria for HSCT-Associated Thrombotic Microangiopathy: A Study in Children and Young Adults. Blood, 124, 645-653. [Google Scholar] [CrossRef] [PubMed]
[26] Fuge, R., Bird, J.M., Fraser, A., et al. (2001) The Clinical Features, Risk Factors and Outcome of Thrombotic Thrombocytopenic Purpura Occurring after Bone Marrow Trans-plantation. British Journal of Haematology, 113, 58-64. [Google Scholar] [CrossRef] [PubMed]
[27] Au, W.Y., Ma, E.S., Lee, T.L., et al. (2007) Successful Treatment of Thrombotic Microangiopathy after Haematopoietic Stem Cell Transplantation with Rituximab. British Journal of Haematology, 137, 475-478. [Google Scholar] [CrossRef] [PubMed]
[28] Carella, A.M., D’Arena, G., Greco, M.M., Nobile, M. and Cascavilla, N. (2008) Rituximab for Allo-SCT-Associated Thrombotic Thrombocytopenic Purpura. Bone Marrow Transplantation, 41, 1063-1065. [Google Scholar] [CrossRef] [PubMed]
[29] Dhakal, P., Giri, S., Pathak, R. and Bhatt, V.R. (2017) Eculizumab in Transplant-Associated Thrombotic Microangiopathy. Clinical and Applied Thrombosis/Hemostasis, 23, 175-180. [Google Scholar] [CrossRef] [PubMed]
[30] Rudoni, J., Jan, A., Hosing, C., et al. (2018) Eculizumab for Transplant-Associated Thrombotic Microangiopathy in Adult Allogeneic Stem Cell Transplant Recipients. European Journal of Haematology, 101, 389-398. [Google Scholar] [CrossRef] [PubMed]
[31] Kim, S.S., Patel, M., Yum, K., et al. (2015) Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy: Review of Pharmacologic Treatment Options. Transfusion, 55, 452-458. [Google Scholar] [CrossRef] [PubMed]
[32] Jodele, S., Fukuda, T., Vinks, A., et al. (2014) Eculizumab Ther-apy in Children with Severe Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 20, 518-525. [Google Scholar] [CrossRef] [PubMed]
[33] Corti, P., Uderzo, C., Tagliabue, A., et al. (2002) Defibrotide as a Promising Treatment for Thrombotic Thrombocytopenic Purpura in Patients Undergoing Bone Marrow Transplantation. Bone Marrow Transplantation, 29, 542-543. [Google Scholar] [CrossRef] [PubMed]
[34] Uderzo, C., Bonanomi, S., Busca, A., et al. (2006) Risk Factors and Severe Outcome in Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation. Trans-plantation, 82, 638-644. [Google Scholar] [CrossRef] [PubMed]
[35] Devadas, S.K., Toshniwal, M., Bagal, B., et al. (2018) Successful Treatment of Transplant Associated Thrombotic Microangiopathy (TA-TMA) with Low Dose Defibrotide. Indian Journal of Hematology and Blood Transfusion, 34, 469-473. [Google Scholar] [CrossRef] [PubMed]
[36] Laberko, A., Aksenova, M., Shipitsina, I., et al. (2020) Serious Hemorrhagic Complications after Successful Treatment of Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy with Defibrotide in Pediatric Patient with Myelodysplastic Syndrome. Frontiers in Pedi-atrics, 8, Article No. 155. [Google Scholar] [CrossRef] [PubMed]

为你推荐